Syndax Pharmaceuticals, Inc.

As of September 8, 2025, Syndax Pharmaceuticals, Inc. shows a mildly bearish trend due to mixed signals from various indicators, with underperformance against the S&P 500 over the past week and month.

As of August 1, 2024, Syndax Pharmaceuticals is considered risky and overvalued due to its high Price to Book Value of 4.58, negative EV to EBIT and EV to EBITDA ratios, and alarmingly low ROCE and ROE, while it has significantly underperformed the S&P 500 over the past year and three years.

As of August 1, 2024, Syndax Pharmaceuticals is considered overvalued and risky, with concerning financial ratios and a year-to-date return of -30.48%, significantly underperforming the S&P 500.

As of May 6, 2025, Syndax Pharmaceuticals, Inc. exhibits a strong bearish trend supported by negative indicators across weekly and monthly MACD, Bollinger Bands, moving averages, and KST.

As of March 2022, the management team of Syndax Pharmaceuticals, Inc. includes CEO Dr. Briggs Morrison, President Michael Metzger, and several independent directors, including Mr. Dennis Podlesak as Chairman. They oversee the company's operations and strategic direction.

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing combination therapies for cancer. As of March 2025, it reported net sales of $20 million and a net loss of $85 million, with a market cap of $829.50 million.

As of Jun 18, Syndax Pharmaceuticals, Inc. has a market capitalization of 829.50 million, with net sales of 43.72 million and a net loss of 331.21 million over the latest four quarters. Shareholder's funds are reported at 288.12 million, and total assets amount to 724.82 million.